ArticleJournal of leukocyte biology2026
Basal activation of ERK1/2 blunts the antimicrobial activity of neutrophils from old hosts against antibody-opsonized Streptococcus pneumoniae.
Article in Journal of leukocyte biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
- Update of
Authors and funding
3 authors.
Funding
Abstract
Age-related decline in neutrophil function reduces vaccine protection against Streptococcus pneumoniae. In vaccinated hosts, neutrophil activation via complement and Fcγ receptors mediates bacterial uptake and killing. Mechanisms behind age-related changes in signaling of these receptors is unknown. Using neutrophils from young and old mice, we found opsonin-dependent differences in mitogen-activated protein kinase (MAPK) activation. Neutrophils from old mice had higher basal phosphorylation of MAPK proteins than those of young control mice, including a 15-fold increase in phosphorylated extracellular signal-regulated kinase 1/2 (ERK1/2), but did not increase phosphorylation upon infection with antibody-opsonized bacteria. Inhibition of ERK1/2 signaling blunted killing of antibody-opsonized pneumococci by neutrophils from young mice but improved killing in old mice. In young adult human participants, inhibition of ERK1/2 signaling in neutrophils decreased pneumococcal killing, but only in vaccinated hosts, demonstrating the clinical relevance of this pathway. This study demonstrates that balanced activation of ERK1/2 is crucial for neutrophil antimicrobial activity against antibody-opsonized bacteria but is disrupted in old hosts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.